JP2024522990A5 - - Google Patents
Info
- Publication number
- JP2024522990A5 JP2024522990A5 JP2023574150A JP2023574150A JP2024522990A5 JP 2024522990 A5 JP2024522990 A5 JP 2024522990A5 JP 2023574150 A JP2023574150 A JP 2023574150A JP 2023574150 A JP2023574150 A JP 2023574150A JP 2024522990 A5 JP2024522990 A5 JP 2024522990A5
- Authority
- JP
- Japan
- Prior art keywords
- mixtures
- tautomers
- item
- enantiomers
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195930P | 2021-06-02 | 2021-06-02 | |
| US63/195,930 | 2021-06-02 | ||
| US202163275113P | 2021-11-03 | 2021-11-03 | |
| US63/275,113 | 2021-11-03 | ||
| PCT/US2022/031815 WO2022256434A1 (en) | 2021-06-02 | 2022-06-01 | Protease inhibitors as antivirals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522990A JP2024522990A (ja) | 2024-06-25 |
| JP2024522990A5 true JP2024522990A5 (cg-RX-API-DMAC10.html) | 2025-06-10 |
Family
ID=82321542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574150A Pending JP2024522990A (ja) | 2021-06-02 | 2022-06-01 | 抗ウイルス薬としてのプロテアーゼ阻害剤 |
Country Status (12)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4635972A3 (en) * | 2020-07-20 | 2025-12-24 | Enanta Pharmaceuticals, Inc. | Functionalized peptides as antiviral agents |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US20240043417A1 (en) * | 2020-12-01 | 2024-02-08 | Purdue Research Foundation | Compounds for the treatment of sars |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| JP2024522990A (ja) | 2021-06-02 | 2024-06-25 | エイシア セラピューティクス， インコーポレイテッド | 抗ウイルス薬としてのプロテアーゼ阻害剤 |
| US12643905B2 (en) | 2021-07-23 | 2026-06-02 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023093834A1 (zh) * | 2021-11-26 | 2023-06-01 | 先声再明医药有限公司 | 一种吡咯烷类抗病毒化合物 |
| WO2023107417A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| TW202334123A (zh) * | 2021-12-31 | 2023-09-01 | 大陸商蘇州愛科百發生物醫藥技術有限公司 | 用於預防和治療冠狀病毒感染的化合物及其偶聯物和方法 |
| WO2023134730A1 (zh) * | 2022-01-13 | 2023-07-20 | 先声再明医药有限公司 | 一种酰胺类抗病毒化合物 |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN116535460A (zh) * | 2023-04-28 | 2023-08-04 | 中国人民解放军军事科学院军事医学研究院 | 一类含硫拟肽类化合物及其制备方法和用途 |
| WO2024237816A1 (ru) * | 2023-05-12 | 2024-11-21 | Общество С Ограниченной Ответственностью "Промомед Рус" | Новые производные азабициклогексана |
| WO2025011610A1 (zh) * | 2023-07-13 | 2025-01-16 | 深圳市塔吉瑞生物医药有限公司 | 酰胺衍生物及其组合物及用途 |
| EP4686470A1 (en) | 2024-08-01 | 2026-02-04 | Ospedale San Raffaele S.r.l. | Macrocyclic peptidomimetics as antiviral agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004312547A1 (en) * | 2003-12-31 | 2005-07-21 | Taigen Biotechnology | Protease inhibitors |
| WO2005113580A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| WO2006061714A2 (en) | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| CN110818691A (zh) | 2018-08-09 | 2020-02-21 | 中国科学院上海药物研究所 | 酮酰胺类化合物及其制备方法、药物组合物和用途 |
| WO2020247565A1 (en) | 2019-06-05 | 2020-12-10 | Rhodia Operations | Oral care composition |
| AU2020289560A1 (en) | 2019-06-05 | 2021-12-23 | Emory University | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
| US12485157B2 (en) * | 2020-04-05 | 2025-12-02 | Pfizer Inc. | Method of treating COVID-19 |
| IL297069A (en) * | 2020-04-10 | 2022-12-01 | Cocrystal Pharma Inc | Replication inhibitors of norovirus and corona virus |
| US11124497B1 (en) * | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| CN115667209A (zh) * | 2020-04-23 | 2023-01-31 | 普渡研究基金会 | 用于治疗sars的化合物 |
| GB2595975B (en) * | 2020-06-09 | 2022-12-07 | Pardes Biosciences Inc | Inhibitors of cysteine proteases and methods of use thereof |
| CN116547294A (zh) * | 2020-08-13 | 2023-08-04 | 英安塔制药有限公司 | 作为抗病毒剂的功能化肽 |
| US11351149B2 (en) * | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| JP2024522990A (ja) | 2021-06-02 | 2024-06-25 | エイシア セラピューティクス， インコーポレイテッド | 抗ウイルス薬としてのプロテアーゼ阻害剤 |
-
2022
- 2022-06-01 JP JP2023574150A patent/JP2024522990A/ja active Pending
- 2022-06-01 MX MX2023014307A patent/MX2023014307A/es unknown
- 2022-06-01 EP EP22735725.8A patent/EP4347034A1/en active Pending
- 2022-06-01 BR BR112023025358A patent/BR112023025358A2/pt unknown
- 2022-06-01 WO PCT/US2022/031815 patent/WO2022256434A1/en not_active Ceased
- 2022-06-01 AU AU2022283816A patent/AU2022283816A1/en active Pending
- 2022-06-01 CN CN202610393263.6A patent/CN122277534A/zh active Pending
- 2022-06-01 CA CA3220847A patent/CA3220847A1/en active Pending
- 2022-06-01 KR KR1020237045446A patent/KR20240057384A/ko active Pending
- 2022-06-01 TW TW111120433A patent/TW202313567A/zh unknown
- 2022-06-01 IL IL308694A patent/IL308694A/en unknown
- 2022-06-01 US US17/830,185 patent/US11753373B2/en active Active
-
2023
- 2023-06-15 US US18/210,555 patent/US11987554B2/en active Active
-
2024
- 2024-04-22 US US18/642,453 patent/US20250122153A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2818820B2 (ja) | 抗炎症剤としての３−アリール−２−イソオキサゾリン類 | |
| JP2021534124A5 (cg-RX-API-DMAC10.html) | ||
| US7683094B2 (en) | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | |
| TW201431865A (zh) | 硼酸衍生物及其治療用途 | |
| ES2662894T3 (es) | Derivados de 2H-indazol antibacterianos | |
| JP2010265292A (ja) | ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法 | |
| JPH11509175A (ja) | Ｎ−ヘテロアリールピリジンスルホンアミド誘導体およびエンドテリンアンタゴニストとしてのそれらの使用 | |
| RU2010101611A (ru) | Полициклические производные гуанина и способы их применения | |
| JP2023533855A5 (cg-RX-API-DMAC10.html) | ||
| KR101346527B1 (ko) | 아민 화합물 및 그 의약 용도 | |
| JP2002526527A (ja) | タキキニン受容体拮抗剤としてのナフタレンカルボキシアミド | |
| KR20180011843A (ko) | 유출-펌프 억제제 및 이의 치료적 용도 | |
| EP0652884B1 (en) | Phosphonated arylethanolamine compounds with anti-hyperglycemic and/or anti-obesity activity | |
| JPWO2011125836A1 (ja) | 線維筋痛症の治療剤又は予防剤 | |
| JP2022048391A (ja) | インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物 | |
| RU2627361C2 (ru) | Биарил- или гетероциклические биарилзамещенные производные циклогексена в качестве ингибиторов сетр | |
| TW201938517A (zh) | 苯並雜環化合物及其用途 | |
| RU2732417C1 (ru) | Производные фенотиазина и способы их применения | |
| TH67821A (th) | สารรักษาโรคชนิดใหม่เพื่อการรักษาโรคปอดที่เกิดภาวะอุดตันเรื้อรัง | |
| TH66454B (th) | สารรักษาโรคชนิดใหม่เพื่อการรักษาโรคปอดที่เกิดภาวะอุดตันเรื้อรัง | |
| TH2101006585A (th) | ตัวควบคุมพาธเวย์การตอบสนองความเค้นรวม | |
| HK40033744B (en) | Compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| ZA200102651B (en) | Naphthalenecarboxamides as tachykinin receptor antagonists. | |
| AU2014200986A1 (en) | 4-hydroxybutyric acid analogs | |
| NZ625636A (en) | Novel pyrrole derivatives |